Evidence map›Paper›PMID 22952275›Full record

ArticleBMJ case reports2012

Dramatic response to inhaled dobesilate in a patient with lung squamous cell cancer.

Pedro Cuevas, Antonio Sueiro, Pilar Navío, Guillermo Giménez-Gallego

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Pedro CuevasDepartamento de Investigación, IRYCIS, Madrid, Spain. pedro.cuevas@hrc.es
Antonio Sueiro
Pilar Navío
Guillermo Giménez-Gallego
Hospital Universitario Ramón y Cajal · ESConsejo Superior de Investigaciones Científicas · ESInstituto Ramón y Cajal de Investigación Sanitaria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of local application, by inhalation, of dobesilate, an inhibitor of fibroblast growth factor signalling, in a patient with squamous cell lung carcinoma is reported. To our knowledge, these are the first published data on the efficacy of dobesilate in the treatment of this disease. The antimitotic, antiangiogenic, proapoptotic and anti-inflammatory activities of dobesilate can be important factors to consider, in explaining the efficacy of the treatment. Dobesilate administration can be a therapeutic option in patients with lung cancer having poor performance status or severe complications.

Indexed as

Administration, InhalationAgedAntineoplastic AgentsCalcium DobesilateCarcinoma, Squamous CellHumansLungLung NeoplasmsMaleAntineoplastic AgentsCalcium Dobesilate

Identifiers

PMID22952275
PMCPMC4544079
OpenAlexW2121622538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.